Redefining the role of digoxin in the treatment of atrial fibrillation

The American Journal of Cardiology

Volumn 69, Issue 18, 1992, Pages 71-81

  Sarter, Brian H ^a,b   Marchlinski, Francis E ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM ION; DIGOXIN; DILTIAZEM; ESMOLOL; NADOLOL; NIFEDIPINE; POTASSIUM ION; PRACTOLOL; SODIUM ION; TIMOLOL; VERAPAMIL;

AUTONOMIC NERVOUS SYSTEM; DIGITALIZATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE FAILURE; HUMAN; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; WOLFF PARKINSON WHITE SYNDROME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CHRONIC DISEASE; DIGOXIN; DRUG THERAPY, COMBINATION; ELECTROPHYSIOLOGY; HUMAN; INFANT, NEWBORN; PREMEDICATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026749888     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(92)91256-4     Document Type: Article

References (51)

1. Digitalis and the autonomic nervous system
2. Frequency-dependent effects of diltiazem on the atrioventricular node during experimental atrial fibrillation
3. Electrophysiologic effects of intravenous metoprolol
4. Effects of digitalis on cell biochemistry sodium pump inhibition
5. Digitalis: mechanisms of action and clinical use
6. Cellular mechanism of cardiac glycosides
7. The action of cardiac glycosides on the refractory period of heart tissues
8. Cellular electrophysiology of digitalis toxicity
9. Electrophysiology and pharmacology of cardiac arrhythmias. IV. Cardiac antiarrhythmic and toxic effects of digitalis
10. Effects of digitalis on atrial vulnerability
11. Effect of digoxin on atrioventricular conduction
12. Depressant effect of digoxin on atrioventricular conduction in man
13. Effects of digitalis on the functional refractory period of the AV node studies in awake dogs with and without cardiac denervation
14. Cardiac arrhythmias
15. Cardiac arrhythmias
16. Cardiac arrhythmias
17. Time of occurrence, duration and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin
18. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation
19. Clinical course of acute atrial fibrillation treated with rapid digitalization
20. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm
21. Clinical pharmacokinetics of digitalis glycosides
22. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation
23. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis—a randomized cross-over study
24. Relative efficacy of oral verapamil and digoxin alone or in combination for the treatment of patients with chronic atrial fibrillation
25. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent
26. Efficacy and safety of medium and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation
27. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation
28. Cardiac arrhythmias following pneumonectomy
29. Cardiac dysrhythmias after thoracotomy
30. Arrhythmias following cardiac surgery relations to serum digoxin levels
31. Complications of prophylactic digitalization in thoracic surgical patients
32. Supraventricular tachyarrhythmias after myocardial revascularization: a randomized trial of prophylactic digitalization
33. Prophylactic digitalization for coronary artery bypass surgery
34. Prevention of supraventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized control trials
35. Comparative effects of three calcium antagonists, diltiazem, verapamil, and nifedipine, on the sinoatrial and atrioventricular nodes
36. Propranolol for the prevention of postoperative cardiac arrhythmias. A randomized study
37. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter
38. Verapamil for control of ventricular rate of paroxysmal supraventricular tachycardia and atrial fibrillation or flutter—a double-blind randomized cross-over study
39. Comparative efficacy and tolerance of esmolol to propranolol for control of supraventricular tachyarrhythmia
40. Comparison of the efficacy and safety of esmolol a short-acting beta blocker with placebo in the treatment of supraventricular tachyarrhythmias
41. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter
42. Effects of nadolol on the spontaneous and exercise provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin
43. Beta adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation
44. Cardiomyopathy and specific heart muscle disease
45. Hypertrophic Cardiomyopathy interrelations of clinical manifestations, pathophysiology and therapy
46. Digitalis in the pre-excitation syndrome—analysis during atrial fibrillation
47. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atriofibrillation and atrial flutter: A multicenter study
48. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation
49. The electrophysiologic effects of intramuscular quinidine in the atriovehtricular conducting system in man
50. Quinidine induced ventricular flutter and fibrillation without digitalis therapy
51. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation